Terms: = Leukemia AND ARID1B, 6A3-5, 57492, ENSG00000049618, p250R, KIAA1235, ELD/OSA1, DAN15, BRIGHT, BAF250b AND Treatment
95 results:
1. A Bizarre Progression Of Chronic Lymphocytic Leukaemia Into Diffuse Large B-Cell Lymphoma.
Shakeel D; Qadir H; Baig MM; Ojla SM
J Ayub Med Coll Abbottabad; 2023; 35(3):512-514. PubMed ID: 38404107
[TBL] [Abstract] [Full Text] [Related]
2. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes.
Izutsu K; Ubukawa K; Morishita T; Onishi Y; Ishizawa K; Fujii Y; Kimura N; Yokochi M; Naoe T
Cancer Sci; 2024 Apr; 115(4):1250-1260. PubMed ID: 38327103
[TBL] [Abstract] [Full Text] [Related]
3. The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders.
Al-Zubaidi HK; Hughes SF
Br J Biomed Sci; 2023; 80():11573. PubMed ID: 37822353
[No Abstract] [Full Text] [Related]
4. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 bright AML 1019 trial.
Sekeres MA; Montesinos P; Novak J; Wang J; Jeyakumar D; Tomlinson B; Mayer J; Jou E; Robak T; Taussig DC; Dombret H; Merchant A; Shaik N; O'Brien T; Roh W; Liu X; Ma W; DiRienzo CG; Chan G; Cortes JE
Leukemia; 2023 Oct; 37(10):2017-2026. PubMed ID: 37604981
[TBL] [Abstract] [Full Text] [Related]
5. Acute myeloid leukemia with RAM immunophenotype: A new underdiagnosed entity.
Gajendra S; Anupurba S; Gupta R; Mallick S; Panda D; Thakral D; Gupta SK; Bakhshi S; Seth R; Rai S; Prajapati VK; Singh S
Int J Lab Hematol; 2023 Aug; 45(4):541-552. PubMed ID: 37078511
[TBL] [Abstract] [Full Text] [Related]
6. A bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies.
Newman H; Teachey DT
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955734
[TBL] [Abstract] [Full Text] [Related]
7. The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
Xu Z; Yin J; Sun Q; Hu J; Hong M; Qian S; Liu W
Leuk Lymphoma; 2022 Nov; 63(11):2616-2626. PubMed ID: 35758278
[TBL] [Abstract] [Full Text] [Related]
8. Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission.
Yu G; Lu W; Chen X; Li Y; Long J; Zheng Z; Yin C; Xu D
Leuk Lymphoma; 2022 Nov; 63(11):2604-2615. PubMed ID: 35695125
[TBL] [Abstract] [Full Text] [Related]
9. Mechanisms Involved in the Promoting Activity of Fibroblasts in HTLV-1-Mediated Lymphomagenesis: Insights into the Plasticity of Lymphomatous Cells.
Rigotto G; Montini B; Mattiolo A; Lazzari N; Piano MA; Remondini D; Marmiroli S; Bertacchini J; Chieco-Bianchi L; Calabrò ML
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638901
[TBL] [Abstract] [Full Text] [Related]
10. The changing landscape for patients with relapsed/refractory acute myeloid leukaemia.
Isidori A; Ferrara F
Curr Opin Oncol; 2021 Nov; 33(6):635-641. PubMed ID: 34474436
[TBL] [Abstract] [Full Text] [Related]
11. Forsaken Pharmaceutical: Glasdegib in Acute Myeloid leukemia and Myeloid Diseases.
Feld J; Silverman LR; Navada SC
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e415-e422. PubMed ID: 33547022
[TBL] [Abstract] [Full Text] [Related]
12. The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada.
Hu Y; Charaan M; van Oostrum I; Heeg B; Bell T
J Med Econ; 2021; 24(1):150-161. PubMed ID: 33461352
[TBL] [Abstract] [Full Text] [Related]
13. [Expression of Costimulatory Molecule Tim3 on NK Cells and Its Subsets in Patients with Acute Myeloid leukemia].
Wu WH; Shao JW; Jiang YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1899-1903. PubMed ID: 33283717
[TBL] [Abstract] [Full Text] [Related]
14. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
Lin S; Shaik N; Chan G; Cortes JE; Ruiz-Garcia A
Cancer Chemother Pharmacol; 2020 Oct; 86(4):451-459. PubMed ID: 32885274
[TBL] [Abstract] [Full Text] [Related]
15. Imidazo[1,2-
Kotogány E; Balog JÁ; Nagy LI; Alföldi R; Bertagnolo V; Brugnoli F; Demjén A; Kovács AK; Batár P; Mezei G; Szabó R; Kanizsai I; Varga C; Puskás LG; Szebeni GJ
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698503
[TBL] [Abstract] [Full Text] [Related]
16. Microfluidic Chip based direct triple antibody immunoassay for monitoring patient comparative response to leukemia treatment.
İçöz K; Akar Ü; Ünal E
Biomed Microdevices; 2020 Jul; 22(3):48. PubMed ID: 32661698
[TBL] [Abstract] [Full Text] [Related]
17. Label-Free leukemia Monitoring by Computer Vision.
Doan M; Case M; Masic D; Hennig H; McQuin C; Caicedo J; Singh S; Goodman A; Wolkenhauer O; Summers HD; Jamieson D; Delft FV; Filby A; Carpenter AE; Rees P; Irving J
Cytometry A; 2020 Apr; 97(4):407-414. PubMed ID: 32091180
[TBL] [Abstract] [Full Text] [Related]
18. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
[TBL] [Abstract] [Full Text] [Related]
19. The evolving treatment landscape of chronic lymphocytic leukemia.
Schiattone L; Ghia P; Scarfò L
Curr Opin Oncol; 2019 Nov; 31(6):568-573. PubMed ID: 31593975
[TBL] [Abstract] [Full Text] [Related]
20. Glasdegib in the treatment of acute myeloid leukemia.
Wolska-Washer A; Robak T
Future Oncol; 2019 Oct; 15(28):3219-3232. PubMed ID: 31432695
[TBL] [Abstract] [Full Text] [Related]
[Next]
